Skip to main content
Equibles
VTGN logo

VTGN · Vistagen Therapeutics, Inc. · Metrics

Track VTGN — free

Use VTGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VTGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.17 0.00 (-0.40%) Q3 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As of June 30, 2026, we had cash, cash equivalents, and marketable securities of approximately $31.7 million. As of August 14, 2026, the issuance date of the condensed consolidated financial statements in this Quarterly Report as of and for the three months ended June 30, 2026, there is uncertainty about whether our combined cash, cash equivalents, and marketable securities will be sufficient to fund operations beyond twelve months from the issuance date of the condensed consolidated financial statements in this Report and therefore we concluded that substantial doubt exists about our ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$7.46M
Shares
44.38M
Volume · Oct 28 860.29K Avg daily vol (3M) 12.15M

VTGN metrics

78 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.17
Market cap
$7.46M

Price action

20 metrics
Price change (1W)
-12.0%
Price change (30D)
-41.4%
Price change (3M)
-24.3%
Price change (6M)
-71.0%
Price change (YTD)
-73.6%
Price change (1Y)
-95.5%
Trailing year
Price change (5Y)
—
52-week high
$4.90
52-week low
$0.17
Change from 52-week high
-96.4%
Change from 52-week low
+0.1%
Annualized volatility
141.5%
Annualized volatility (3M)
122.0%
Beta
1.4
RSI (14D)
30.6
Price vs SMA 50
-28.1%
Price vs SMA 200
-61.6%
Avg volume (3M)
12.17M
Relative volume
0.1
Average dollar volume
$4.20M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
44.38M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
-3.7×
EV / EBITDA
—
EV / EBIT
—
P / sales
3.1×
reciprocal yield 32.4%
P / book
0.3
reciprocal yield 317.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-875.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
16.1×
reciprocal yield 6.2%
EV / revenue historical average (5Y)
39.9×
reciprocal yield 2.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-06-30

Profitability

9 metrics
Gross margin
—
Operating margin
-2,785.7%
Trailing 12 months
Net margin
-2,703.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$69.67M
Net income (TTM)
−$67.62M
Trailing 12 months
Diluted EPS (TTM)
$-1.66
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.06
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.73
EBITDA per diluted share (TTM)
$-1.72
Net income per diluted share (TTM)
$-1.68
Operating cash flow per diluted share (TTM)
$-1.53
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$1.35
Stock compensation per diluted share (TTM)
$0.10
Book value per share
$-9.15

Growth

11 metrics
Revenue growth YoY
+504.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.50M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+34.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
+3.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-276.2%
Return on assets
-189.2%
Debt / equity
0.0
Current ratio
3.1
EBITDA (TTM)
−$69.46M
Free cash flow (TTM)
—
Quick ratio
3.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$16.99M
Latest balance sheet
Cash & equivalents
$16.99M
Total assets
$35.74M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$62.30M
Capital expenditures (TTM)
$528,000
R&D (TTM)
$54.20M
SG&A (TTM)
—
Stock compensation (TTM)
$4.07M
R&D / revenue
2,167.2%
Stock compensation / revenue
162.8%

Ownership (13F)

9 metrics
13F filers
53
13F filer change QoQ
-4
Institutional ownership
29.4%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
18.8%
Private-fund adviser ownership
15.0%
Active holders' share change QoQ
-23.4%
Holder tenure
5.6
Price vs estimated holder cost
-77.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.4%

Short interest

3 metrics
Short interest
5.6%
Latest settlement · 2.2 days to cover
Days to cover
2.2d
Short-squeeze score
42 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1411685 CUSIP 92840H400 13F (30d) 3 filings 3 filers Visit website Investor relations